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Amiodarone-induced thryrotoxicosis (AIT) is a rare but serious complication of amiodarone use, especially in patients with
severe cardiac disease. We present a patient who developed AIT, following administration of amiodarone for life-threatening
ventricular arrhythmias. We discuss the medical management of AIT and anesthetic considerations for management of patients
with thyrotoxicosis and severe cardiac disease who require surgery including thyroidectomy.
1.Introduction
Amiodarone is an eﬀective antiarrhythmic drug. It has a
number of side eﬀects including thyroid dysfunction, due
to its high iodine content and direct toxic eﬀect on the
thyroid. Amiodarone is frequently used in patients with
supraventricular and ventricular arrhythmias [1].
AITisrarebutseeninpatientswithseverecardiacdisease
since it is predominately used in this population. AIT has
multiple eﬀects on a patient’s physical condition including
on cardiac performance. Current treatment options include
medicaltherapyandthyroidectomy.Anestheticmanagement
of patients with AIT and poor cardiac function is challeng-
ing. Here, we report the management of a patient with AIT
andseverecardiacdisease.Anestheticmanagementincluding
techniques and potential complications is discussed.
2.CaseReport
A 46-year-old man with idiopathic dilated cardiomyopathy
was admitted for the treatment of sustained ventricular
tachycardia using radiofrequency ablation. Echocardiogra-
phy showed left ventricular dilatation, left ventricular ejec-
tion fraction of 30%, normal right-sided chambers, and mild
mitral regurgitation. Coronary angiogram demonstrated
normal coronary arteries. Two years earlier he had been
successfullyresuscitatedfollowingcollapseduetoventricular
ﬁbrillation and had an implantable cardioverter-deﬁbrillator
(ICD) placed. Due to persistent episodes of ventricular
tachycardia and ventricular ﬁbrillation, treatment with
amiodarone was initiated. Ventricular arrhythmias persisted
and attempts were made at radiofrequency ablation, but
were unsuccessful. Cryoablation by way of sternotomy was
successfully performed, although the postoperative period
was complicated with mediastinitis requiring antibiotic
treatmentandvacuum-assistedclosureofthewound.Several
days postoperatively the patient complained of a ﬁne tremor
of the hands and tachycardia. Thyroid function tests (TFTs)
demonstrated an increased free T4 of >99.9pmol/L (10–
24pmol/L), a normal T3 of 2.5nmol/L (1.1–3.1nmol/L),
a n dad e c r e a s e dT S Ho f<0.005mU/l (0.3–4.8mU/L). The
diagnosis AIT was made. Amiodarone therapy was stopped
and the patient started on propylthiouracil. One week later,
sodiumperchlorate was added as free T4 and TSH levels were
unaltered, but T3 level increased to 6.5nmol/L. The follow-
ing week prednisone was added as T3 and free T4 remained
high. Metoprolol was increased. Despite receiving triple
therapy for AIT, there was no improvement in the TFTs.
Due to concerns regarding the duration of hyperthyroidism
and its potential eﬀects on cardiac function a decision was
made to perform a thyroidectomy. Four weeks after the
initial sternotomy, thyroid surgery was performed. Because2 Case Reports in Medicine
of the combination of closure of the sternal wound and
thyroidectomyandlittleexperienceofperformingthyroidec-
tomy under locoregional anesthesia, surgery was performed
under general anesthesia. The patient was premedicated
with lorazepam 2mg sublingual. Etomidate 0.25mg/kg and
fentanyl 2mcg/kg were used for induction because of
their cardio-stabile proﬁles. Atracurium 0.5mg/kg was given
to facilitate intubation. Anesthesia was maintained using
propofol and remifentanyl, titrated to maintain a bispectral
index between 40 and 45%. Morphine 0, 15mg/kg was given
for postoperative pain. No complications were seen during
or after surgery. Within several weeks after the procedure,
TFTsimprovedandthepatientwasstartedonthyroxine.The
patient was discharged to another hospital for rehabilitation.
3. Discussion
Amiodarone is a class III antiarrhythmic drug which is
widely used for ventricular and supraventricular arrhyth-
mias. Amiodarone has a range of side eﬀects which include
interstitial pneumonitis, cardiac disorders, and thyroid dys-
function [1, 2]. Both hypothyroidism and hyperthyroidism
are recognized and can occur in up to 25% of patients
[3]. The average prevalence for AIT is about 5% with a
maximum of up to 27% described [1, 4]. Thyrotoxicosis
is diagnosed by clinical signs and thyroid function tests.
Symptoms include weight loss, decreased appetite, frequent
stools, tremor, emotional liability, and heat intolerance.
Physical examination demonstrates tachycardia, ﬁne tremor,
thyroidenlargementornodules,thyroidbruitandmyopathy.
In AIT tiredness and weight loss predominate due to
amiodarone-mediated alpha and beta adrenergic blockade.
Thyroid function tests most commonly show a low thyroid-
stimulating hormone (TSH) level and high thyroxine and T3
levels.
Management of AIT is a challenge, involving three ther-
apeutic options [5]. The ﬁrst involves discontinuing amio-
darone use. This may not be an option if there are no further
treatment options available for the underlying arrhythmia.
One case review states that 5% of the patients treated
with amiodarone for an arrhythmia are refractory to other
treatments [4]. In addition improvements in thyrotoxicosis
take several months after cessation of amiodarone therapy.
A rebound rise in T3 and loss of the beta blockade may
exacerbate thyrotoxicosis on stopping amiodarone therapy.
The second option is medical treatment, including
thionamides, perchlorates, and corticosteroids. Thionamides
block hormone synthesis by interfering with iodine organ-
iﬁcation and the coupling of iodothyrosines. Perchlorates
competitively block iodide from entering the thyroid gland.
Corticosteroids suppress the eﬀects of autoimmune thy-
rotoxicosis. Treatment may take as long as 4 months to
become eﬀective. Other medical options include radioiodine
and iopanoic acid, which inhibits peripheral conversion
of T4 to T3. Plasmapheresis can temporarily improve the
clinical situation in cases of severe thyrotoxicosis refractory
to medical treatment. In addition to antithyroid medication,
symptomatic treatment of tachycardia with beta-blockers
Table 1: Drugs in thyroid treatment and side eﬀects.
Medication Side eﬀects
Propylthiouracil/Strumazol
Hepatotoxicity, vasculitis,
agranulocytosis, anaemia,
thrombocytopaenia
Potassium perchlorate Aplastic anaemia
Corticosteroids
Electrolyte disturbances, cardiac
failure, cardiomyopathy, gastric
ulcer, diabetes mellitus
Iopanoic acid
Renal impairment, gastrointestinal
problems, exacerbation
hyperthyroidism
Radioiodine Hyperthyroidism, hypothyroidism
Beta-blockers Bronchospasm, hypotension,
bradycardia, cardiac failure
may be started. Propanolol has the advantage over other
beta-blockers of inhibiting peripheral conversion of T4 to
T3. Beta-blockers given in combination with cordarone can
cause profound bradycardia. Medical treatment can itself
cause side eﬀects (see Table 1).
The third option is surgical treatment. Total or near total
thyroidectomy is a deﬁnitive treatment in thyrotoxicosis.
Thyroidectomy is ideally performed when the patient is
euthyroid. The clinical manifestations of thyrotoxicosis can
occasionally necessitate surgery prior to an euthyroid state.
Thyroid hormones have important inﬂuences on cardiac
function. Increasing levels of T3/T4 cause increased sys-
temic vascular resistance and isovolumic relaxation time to
decreaseandheartrate,ejectionfraction,cardiacoutput,and
blood volume to increase [6]. Hyperthyroidism predisposes
a patient to developing supraventricular arrhythmias, for
example, atrial ﬁbrillation. Dyspnea on exertion and fatigue
develops in approximately 50% of patients. With hyper-
thyroidism patients are generally hypovolemic. In patients
with pre-existing cardiac disease hyperthyroidism may cause
rhythm disturbances, cardiac failure, angina pectoris, and
cardiomyopathy[7].Thyrotoxicosiscanprogresstoathyroid
storm, which is associated with mortality rates of up to 30%.
Thyroid storm may be induced by infection, surgery, iodine
exposition, trauma, pregnancy, and metabolic disorders. The
exact pathogenesis of thyroid storm is not known. Two
potential mechanisms are described. A sudden increase of
free T4 may occur due to a change in T4 protein binding
or altered synthesis of thyroxin binding globulin as occurs
in severe disease like sepsis and ketoacidosis. Alternatively
changes in sympathetic nervous system activation may
induce a thyroid storm. An increase in beta-adrenergic
receptor density and modulation of adrenergic receptor
expression by thyroid hormone can lead to symptoms of a
catecholamine excess [8].
Thyroidectomy in patients with thyrotoxicosis can be
performed under general or local anesthesia. General anes-
thesia provides optimal conditions for the surgeon. It is
associated with some rare but serious complications includ-
ing myocardial infarction, stroke, and even death. General
anesthesia has many side eﬀects including nausea, vomiting,Case Reports in Medicine 3
disorientation, sore throat, shivering, and dizziness [9].
Patients with thyrotoxicosis should continue all antithyroid
medication in the perioperative period. Although beta-
blockers are negatively inotropic and should be used with
care,itsgenerallyadvisedtocontrolcardiovascularresponses
evoked by sympathetic nervous system stimulation with
beta-blockers [10]. For elective surgery long-acting beta-
blockers can be titrated preoperatively until a heart rate
less than 100 beats per minute is achieved. For emergency
surgery intravenous esmolol can be used to achieve the
same goal. Adequate premedication is advised [11, 12]. Oral
benzodiazepines are often used for anxiolysis. Induction of
anesthesia can be achieved with several intravenous induc-
tion agents. Thiopental possesses antithyroid activity but is
cardiodepressant. Ketamine should be avoided in patients
with thyrotoxicosis because it stimulates the sympathetic
nervous system. Neuromuscular blocking agents should
be used cautiously as thyrotoxicosis is associated with an
increased incidence of myopathies. Pancuronium should
be avoided as it is arrhythmogenic [11]. Indirectly acting
adrenergic agonists can cause unexpected rises in blood
pressure and arrhythmias. Phenylephrine is therefore a more
appropriate choice [12]. Monitoring during maintenance
of anesthesia is directed at early recognition of thyroid
storm. Body temperature can rise and hyperpyrexia should
be managed with a cooling mattress and cold intravenous
ﬂuids. ECG monitoring may show tachycardia and cardiac
dysrhythmias which could be treated with intravenous beta-
blockers or lidocaine [11]. In patients with severe cardiac
disease,generalanesthesiacancauseacompromiseincardiac
function with its associated intubation, hypotension, and
negative inotropy. Several studies show general anesthesia
to be safe in patients with AIT and severe cardiac disease.
Haemodynamic changes were rare and thyroid storm was
never encountered [4, 13]. There was no preferential anes-
thetic technique showed.
Use of a local anesthesic technique has the advantage
of avoiding the cardiac stress associated with intubation
and extubation. The side eﬀects of general anesthesia are
prevented. Other beneﬁts include a shorter postoperative
recovery period and reduction of costs [9]. Important
considerations for using a local anesthesic technique are a
cooperative patient, a surgeon accustomed with performing
a thyroidectomy under these circumstances, and no allergy
to local anesthetics. Contraindications include a known
retroesophageal or retrotracheal goitre, concomitant cervical
lymphadenectomy, and known or suspected locally invasive
cancer [14, 15]. Local anesthesia can be accomplished using
a regional block of the cervical plexus combined with
an anterior ﬁeld block or an anterior ﬁeld block alone.
Both are generally combined with conscious sedation and
analgesia using short-acting hypnotics such as propofol and
midazolam and short acting analgesics such as fentanyl
and alfentanil. Spanknebel et al. describe a method of
bilateral superﬁcial cervical plexus blockade combined with
an anterior ﬁeld block for thyroidectomy. Good anesthetic
conditions were obtained with high patient satisfaction
and only a small percentage of patients requiring general
anesthesia [15]. Snyder et al. compared local anesthesia
and general anesthesia for thyroidectomy and found similar
operative results, clinical results, and patient satisfaction
[16]. A retrospective study demonstrated that local anes-
thesia combined with sedation in patients with AIT and
severe cardiac disease was safe [17]. However, the study was
undertaken in a hospital with extensive experience of this
technique for thyroidectomies. Potential complications of
a bilateral superﬁcial plexus blockade include local anes-
thetictoxicity, localizedhematoma,andtemporaryrecurrent
laryngeal nerve paralysis [9].
4. Conclusion
Amiodarone is increasingly used for ventricular and
supraventricluar arrhythmias. AIT will therefore be encoun-
tered more often in patients with cardiac disease. Medical
treatment of thyrotoxicosis should be started in ﬁrst instance
in an attempt to render the patient euthyroid. It is desirable
for the patient to be euthyroid prior to surgery. However,
there is evidence to suggest that general anesthesia can be
safely undertaken in patients with thyrotoxicosis and severe
cardiac disease.
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